FDA advises leveraging what’s already known in gene therapy R&D

#1 · June 3, 2026, 8:51 am

Rather than reinventing the wheel for every gene therapy that uses genome editing, the U.S. FDA is advising sponsors on leveraging existing knowledge, be it publicly available or platform-based, to more efficiently advance their products across multiple stages of development.